WAM
SUPN icon

Weiss Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Weiss Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-35,700
Closed -$230K – 34
2013
Q2 		$230K Buy
+35,700
New +$210K 0.08% 33

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Weiss Asset Management's SUPN Position: Q1 2026 in Review

Weiss Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 39,971 shares — an estimated $1.99M sold.

Weiss Asset Management first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $1.99M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Weiss Asset Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Weiss Asset Management sold 39,971 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.99M.
  • Weiss Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Weiss Asset Management's Supernus Pharmaceuticals position peaked at $1.99M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Weiss Asset Management's 13F filing for Q1 2026, filed 15 May 2026.